ICICI Securities has maintained positive views on four companies following their June-quarter updates, highlighting strong growth levers across multiple sectors. According to reports from NDTV Profit, the brokerage remains constructive on Archean Chemical Industries, GlaxoSmithKline Pharma, MakeMyTrip and Nexus Select Trust, citing improving earnings visibility, growth investments, market-share gains and sustained demand trends. The four companies span different sectors including specialty chemicals, pharmaceuticals, travel technology and retail real estate, demonstrating ICICI Securities' diversified investment strategy across sectors with strong fundamentals and growth prospects.
MakeMyTrip remains one of ICICI Securities' preferred picks in the internet space, with the brokerage maintaining its Buy rating and setting a target price of $74. As reported by NDTV Profit, the recommendation is based on market-share gains in higher-margin non-air segments, resilient travel demand and continued investments in artificial intelligence. The company's diversification into non-air segments is expected to drive margin improvements and sustainable growth, positioning it well for continued expansion in the competitive online travel market.
ICICI Securities retained its Add rating on GSK Pharma and raised its target price to ₹2,900 from ₹2,725. According to the report, the brokerage cited a strong launch pipeline that includes Blenrep and Arexvy, along with expectations of sustained double-digit revenue growth. The pharmaceutical company's focus on specialty drugs and robust product pipeline positions it well for continued expansion in the Indian pharmaceutical market, with the enhanced target reflecting improved confidence in the company's growth trajectory and market positioning.
The four companies span different sectors including specialty chemicals, pharmaceuticals, travel technology and retail real estate. As reported by NDTV Profit, ICICI Securities' approach demonstrates a diversified investment strategy across sectors with strong fundamentals and growth prospects. The brokerage's focus on companies with improving earnings visibility and sustained demand trends suggests confidence in their ability to deliver consistent performance across market cycles, with the latest recommendations reinforcing their positive outlook on these key growth opportunities across various industry segments.
